Piper Sandler Maintains Overweight on Replimune Group, Raises Price Target to $27

Benzinga · 2d ago
Piper Sandler analyst Allison Bratzel maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $14 to $27.